Hematological malignancies

This page contains recent news articles, when available, and an overview of Hematological malignancies but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Hematological malignancies

Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards  -  23 Nov 2009
PR Newswire (press release)Additional risks include bone marrow fibrosis, thrombotic/thromboembolic complications, lack or loss of response to Nplate, and hematological malignancies ...

Two Units Of Umbilical Cord Blood Reduce Risk Of Leukemia Recurrence  -  ‎Nov 14, 2009‎
Science Daily (press release)Blood and marrow stem cell transplantation has been a mainstay treatment for patients with high risk leukemia and other hematological malignancies for the ...

Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.  -  ‎Nov 16, 2009‎
PR Newswire (press release)...focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. ...

ARIAD`s AP24534 Featured in Cancer Cell Publication as a Potential First-in ...  -  ‎Nov 2, 2009‎
Reuters...is now in a Phase 1 dose-escalating clinical trial in patients with refractory CML, acute myeloid leukemia (AML) and other hematological malignancies. ...

Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC ...  -  ‎Nov 4, 2009‎
CNNMoney.com (press release)Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ...

Cyclacel Pharmaceuticals Announces Third Quarter 2009 Financial Results  -  ‎Nov 3, 2009‎
Reuters..."We are working with the FDA to design a registration study for sapacitabine in hematological malignancies. We continue to concentrate our efforts on ...

Allos Therapeutics, Inc., Q3 2009 Earnings Call Transcript  -  ‎Nov 3, 2009‎
Seeking Alpha (blog)FOLOTYN both as a mono-therapy and in combination with other anti-cancer agents in a variety of hematological malignancies and solid tumor indications. ...

Thallion Presents Poster on the Apoptotic Properties of TLN-4601 at the AACR ...  -  ‎Nov 18, 2009‎
Market Wire (press release)...between a liquid tumor cell line and normal human blood lymphocytes suggests that further investigation in hematological malignancies is warranted. ...

New Report Assesses the Commercial Potential of Stem Cell-Based Therapies  -  ‎Nov 11, 2009‎
PRLog.Org (press release)...therapies in all of the key therapeutic areas: autoimmune diseases, cardiovascular, Central Nervous System (CNS) and hematological malignancies. ...

ChemGenex Announces FDA Accepts NDA for Omapro (Omacetaxine Mepesuccinate) and ...  -  ‎Nov 10, 2009‎
PipelineReview.com (press release)Omacetaxine is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. ...

The Miracle of Grape Seed Extract  -  ‎Nov 8, 2009‎
Alternative Health JournalTreatment and prevention of cancers and also other hematological malignancies (cancers of the blood and bone marrow) is an absolute possibility, ...

Notable Mergers and Acquisitions of the Day 11/16: CSCO, MOT, TTMI, ONXX  -  ‎Nov 16, 2009‎
StreetInsider.com (subscription)...focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. ...

Cyclacel Pharmaceuticals Reports Survival Data From Phase 2 Sapacitabine Study ...  -  ‎Oct 29, 2009‎
PipelineReview.com (press release)..."We are currently working with the FDA to design a Phase 3 registration study for sapacitabine in patients with hematological malignancies. ...

Innate Pharma initiates collaboration with Celgene to evaluate the clinical ...  -  ‎Nov 18, 2009‎
PipelineReview.com (press release)...in the field of hematological malignancies�, said Dr. Marcel Rozencweig, Innate Pharma's Senior Vice President, Clinical and Regulatory Strategy. ...

Incyte Reports Third Quarter 2009 Financial Results and Provides Update on ...  -  ‎Nov 5, 2009‎
Reuters...and * an exploratory Investigator initiated Phase II trial in patients with relapsed or refractory hematological malignancies. ...

xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 16, 2009 ...  -  ‎Nov 16, 2009‎
Trading Markets (press release)...focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. ...

EntreMed Reports Second Quarter 2009 Financial Results  -  ‎Aug 6, 2009‎
PR Newswire (press release) (press release)Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies

Cyclacel (CYCC) to Raise Up to $5.9 Million in Registered Direct ...  -  ‎Jul 24, 2009‎
StreetInsider.com (subscription)...the company's lead drug, including a pivotal trial in patients with hematological malignancies," said Spiro Rombotis, President and CEO of Cyclacel.

New Report Just Published Pipeline Insight: Hematological ...  -  ‎Jul 19, 2009‎
Live-PR.com (Pressemitteilung)224 different pipeline products in clinical development for hematological malignancies. Twenty-three (10%) of these drugs are in late-phase studies and are

Reve 21 and Dignitana announce further collaboration  -  ‎Jul 28, 2009‎
Privata Affärer...with hematological malignancies with hematogenic metastases (eg myeloma, leukemia, and lymphoma) should due to possible risk of scalp metastases.

MethylGene Reports Second Quarter 2009 Financial Results  -  ‎Jul 31, 2009‎
Market Wire (press release) (press release)HDAC inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies and is licensed to Taiho Pharmaceutical Co.

OPEN FACULTY POSITIONS  -  ‎Jul 21, 2009‎
Scientist...clinical programs and departments involved in the treatment of solid tumors and hematological malignancies in an NCI-funded Comprehensive Cancer Center.

BUYINS.NET: REGN, ASEI, AIRM, IMGN, EIG, POL Expected To Be Higher ...  -  ‎Aug 3, 2009‎
TMC Net...and colorectal cancer; and IMGN901, which is in three clinical trials for the treatment of multiple myeloma as well as other hematological malignancies,

JAZZ Pharmaceuticals, Ariad and AVI Biopharma Continue Upward ...  -  ‎Jul 28, 2009‎
Small Cap Network...combination with other agents, as well as Phase I clinical trials of AP24534 in patients with refractory CML, AML, and other hematological malignancies.

ChemGenex Appoints Mr. Thomas DeZao as Senior Vice President and ...  -  ‎Jul 21, 2009‎
PharmaLive.com (press release)Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies.

HDAC Inhibitors: emerging drugs in oncology and other indications  -  ‎Jul 12, 2009‎
PipelineReview.com (press release)Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies.

CAL-101, an Oral p110 Isoform-Selective PI3 Kinase Inhibitor ...  -  Dec 8, 2008
MarketWatch..."Our ongoing Phase 1 clinical trial provides our first opportunity to validate this novel approach in patients with hematological malignancies," noted Dr.

ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534 ...  -  Dec 9, 2008
MarketWatchARIAD is conducting a Phase 1 clinical trial of AP24534 in patients with refractory CML, acute myeloid leukemia (AML) and other hematological malignancies.

Immunomedics Reports Preliminary Results of Milatuzumab In ...  -  Dec 8, 2008
MarketWatchThese data demonstrate that milatuzumab is a highly selective therapeutic antibody against CD74 expressing hematological malignancies, but lacks

S*BIO Enters Research Collaboration with Tan Tock Seng Hospital ...  -  Dec 18, 2008
MarketWatchSB1518 might also provide an effective treatment for other hematological malignancies with mutations and re-arrangements in the JAK2 gene.

Experimental Drug Fights Bone Marrow Cancers  -  Dec 9, 2008
Washington Post,...trials as early as 2009," principal investigator Dr. Michael Deininger, head of the hematological malignancies program, said in the news release.

Message from the EditorA new chapter in the cancer tale.  -  Dec 23, 2008
Curetoday.com (press release),This year has brought new drug approvals for treating breast cancer, lung cancer, and hematological malignancies, as well as approvals for various

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 ...  -  Dec 9, 2008
Stockhouse,There is also evidence of activity in hematological malignancies, especially multiple myeloma. Disease stabilization, defined as time on treatment without

Promising New Drug Blocks Mutation In Bone Marrow Cancers  -  Dec 9, 2008
Science Daily (press release)Ph.D., principal investigator and Head of the Hematological Malignancies Program Ph.D. He also is an associate professor of medicine (hematology/medical

New Anti-tumor Gene Identified  -  Dec 16, 2008
Science Daily (press release)Currently, IFNs are relevant in the clinical treatment of a number of solid tumors and hematological malignancies, such as melanoma, renal cell carcinoma,

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly ...  -  Dec 6, 2008
MarketWatchThe study in adult patients with hematological malignancies at high or potential risk for tumor lysis syndrome (TLS) demonstrated that Elitek(R)

Eisai Will Initiate First Head-to-Head Study Comparing Dacogen ...  -  Dec 2, 2008
PharmaLive.com (press release),To advance the understanding of optimal treatment for MDS, hematological malignancies and other cancers, there are currently more than 30 ongoing trials

Chemo Pill Shows Promise for Advanced Lymphoma, Leukemia  -  Dec 8, 2008
Insciences Organisation,Jonathan Friedberg, MD, director of hematological malignancies clinical research, shared results of Phase 1 and 2 clinical trials in the plenary session at

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in ...  -  Dec 8, 2008
MarketWatch...of ofatumumab in both CLL and other disease settings to provide an additional treatment option to patients suffering from hematological malignancies.

Roswell Park Researchers Clarify Mechanisms Of Novel Therapy In ...  -  Dec 9, 2008
Medical News Today (press release),..."As this class of agents moves forward in the treatment of hematological malignancies, the clinical optimization of Obatoclax and its incorporation into

Market Report -- In Play (SNY)  -  Dec 7, 2008
MSN MoneyThe study in adult patients with hematological malignancies at high or potential risk for tumor lysis syndrome demonstrated that Elitek significantly



Background information on Hematological malignancies [When available]

Although hematological malignancies are a form of cancer, they are generally treated by specialists in hematology, although in many hospitals oncology specialists also manage these diseases. ("Hematology/Oncology" is a single subspecialty of Internal Medicine; there are also surgical and radiation oncologists.)

Hematological malignancies are the types of cancer that affect blood, bone marrow and lymph nodes. As the three are intimately connected through the immune system, a disease affecting one of the three will often affect the others as well: although lymphoma is technically a disease of the lymph nodes, it often spreads to the bone marrow, affecting the blood and occasionally producing a paraprotein.

Chromosomal translocations are a common cause of these diseases, while this is uncommon in solid tumors. This leads to a different approach in diagnosis and treatment of hematological malignancies.

Search the web for more resources on Hematological malignancies



Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy